{"id":"W7093123291","doi":"","title":"B03 | PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III MANIFEST-2","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Adverse effect; Placebo; Bone marrow; Randomization; Hemoglobin; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001324518,0.0008000783,0.002057409,0.0003808186,0.0004214644,0.0009670158,0.0006121863,0.0009070418,0.003960359],"category_scores_gemma":[0.0007688078,0.0003858215,0.001031085,0.0003696157,0.0003961422,0.0008728785,0.0003088894,0.001982007,0.001310844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005393545,"about_ca_system_score_gemma":0.0006491306,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006963999,"about_ca_topic_score_gemma":0.001642527,"domain_scores_codex":[0.9996221,0.0001453167,0.00002987547,0.00006000544,0.00003832101,0.0001042956],"domain_scores_gemma":[0.999455,0.00006102464,0.0001453337,0.00005700569,0.00003474765,0.000246777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8006487,0.03057439,0.01127162,0.000479335,0.001126051,0.0002102838,0.00009345321,0.0009177284,0.0211101,0.0001045562,0.004007894,0.1294558],"study_design_scores_gemma":[0.3936629,0.5340246,0.06163991,0.00008226026,0.0007699963,0.0004033309,0.00007342872,0.001495667,0.003617016,0.0002385932,0.003943486,0.00004881174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918116,0.003373975,0.0003381241,0.0003051192,0.00008769841,0.0008662936,0.001417145,0.0001247629,0.0016753],"genre_scores_gemma":[0.9932575,0.0009904532,0.000553874,0.0005616029,0.0001218297,0.0007800562,0.00210277,0.00001807382,0.001613701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003960359,"threshold_uncertainty_score":0.01324874,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0935858793037303,"score_gpt":0.4722885591222656,"score_spread":0.3787026798185353,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}